CSIMarket
 
Merck and Co Inc   (MRK)
Other Ticker:  
 
 
Price: $121.4400 $-0.08 -0.066%
Day's High: $122.51 Week Perf: -0.99 %
Day's Low: $ 121.44 30 Day Perf: -4.03 %
Volume (M): 368 52 Wk High: $ 130.24
Volume (M$): $ 44,955 52 Wk Avg: $111.29
Open: $119.84 52 Wk Low: $99.14



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 68,000
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 377
 Cash Flow (TTM) (Millions $) -4,104
 Capital Exp. (TTM) (Millions $) 2,874

Merck And Co Inc
Merck & Co., Inc.,'is a global research-driven pharmaceutical products company that discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. The Company sells its products primarily to drug wholesalers and retailers, hospitals, clinics, government agencies and managed health care providers such as health maintenance organizations and other institutions. The Company's professional representatives communicate the effectiveness, safety and value of its products to health care professionals in private practice, group practices and managed care organizations.


   Company Address: 126 East Lincoln Avenue Rahway 7065 NJ
   Company Phone Number: 740-4000   Stock Exchange / Ticker: NYSE MRK
   


Customers Net Income fell by MRK's Customers Net Profit Margin fell to

-11.5 %

2.66 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.34%    
ABT   -6.89%    
BMY   -5.17%    
JNJ   -3.67%    
LLY        1.02% 
PFE   -1.04%    
• View Complete Report
   



Product Service News

Merck Expands Oncology Pipeline, Acquires Harpoon Therapeutics and Advances Innovative Treatments for Cancer

Published Mon, Mar 11 2024 12:15 PM UTC

In recent news, pharmaceutical giant Merck has completed the acquisition of Harpoon Therapeutics, enhancing its oncology pipeline and solidifying its position as a leading innovator in cancer treatments. Additionally, Merck Animal Health's injectable formulation of BRAVECTO for dogs has received a positive recommendation from the European Medicines Agency's Committee for Vet...

Product Service News

Investigational Combination Regimen of Islatravir and Lenacapavir Shows Promising Results in Phase 2 Study, Impacts Gilead and Merck's Antiviral Portfolio

Published Wed, Mar 6 2024 3:25 PM UTC

Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, have recently revealed compelling phase 2 data from a clinical trial involving their investigational combination therapy. The study evaluated the efficacy of a once-weekly oral regimen of islatravir (an investigational nucleoside reverse transcriptase translocation inhibitor) and lenacapavir ...

Product Service News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination Therapy for Resectable NSCLC, While Discontinuing KEYLYNK-008 Trial for Metastatic Squamous NSCLC

Published Fri, Feb 23 2024 11:20 AM UTC

Merck, a leading pharmaceutical company, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with platinum-containing chemotherapy. This treatment is intended for patients with resectable non-small cell lung cancer (NSCLC) at high risk of...

Merger and Acquisition

Merck Animal Health to Acquire Elanco's Aqua Business for $13 Billion

Published Mon, Feb 5 2024 11:33 AM UTC

Merck Animal Health to Acquire Elanco's Aqua Business for $1.3 Billion

Merck Animal Health, the division of Merck & Co., Inc., has recently made a significant move in the industry by acquiring the aqua business of Elanco Animal Health Incorporated for an impressive $1.3 billion in cash. This acquisition includes a range of medicines and vaccines, nutritionals, and s...

Merger and Acquisition

Merck Strengthens Oncology Pipeline with $680 Million Acquisition of Harpoon Therapeutics

Published Mon, Jan 8 2024 12:30 PM UTC


Introduction
Pharmaceutical giant Merck (NYSE: MRK) has announced its plans to acquire Harpoon Therapeutics, Inc. (Nasdaq: HARP) for $680 million, aiming to further diversify and strengthen its oncology pipeline. This strategic acquisition comes as Merck continues to enhance its portfolio through targeted expansions, reflecting the company's commitment to advancing ...






 

Merck And Co Inc's Segments
 
Zocor
 Segment     of total Revenue
Zetia
 Segment     of total Revenue
CozaarHyzaar
 Segment     of total Revenue
Singulair
 Segment     of total Revenue
Proscar
 Segment     of total Revenue
Isentress
 Segment     of total Revenue
Primaxin
 Segment     of total Revenue
Remicade
 Segment     of total Revenue
Januvia
 Segment     of total Revenue
Cancidas
 Segment     of total Revenue
Other
 Segment     of total Revenue
Merck Pharmaceutical
 Segment     of total Revenue
Vaccines
 Segment     of total Revenue
All Other
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Merck And Co Inc announced annual revenue outlook on

Earnings Outlook
Merck and Co Inc issued annual earnings guidance on

 
Geographic Revenue Dispersion
United States
EMEA
Japan
Other
Asia Pacific
Latin America




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com